Semaglutide has emerged as one of the most successful peptide therapeutics in history, with global sales expected to reach $39.5 billion in 2026[reference:111]. Its journey from laboratory research to transformative therapy illustrates the potential of peptide drug development and the importance of high-quality research peptides.
Semaglutide is a GLP-1 receptor agonist designed for once-weekly dosing. It was developed through rational design, incorporating a fatty acid moiety that promotes albumin binding and extends half-life. The resulting peptide has a half-life of approximately 7 days, enabling once-weekly subcutaneous administration. An oral formulation (Rybelsus) has also been developed, representing a breakthrough in oral peptide delivery.
Clinical trials have demonstrated the remarkable efficacy of semaglutide. In the SUSTAIN and SELECT trials, semaglutide showed significant reductions in HbA1c, substantial weight loss, and cardiovascular benefits. The SELECT trial specifically demonstrated that semaglutide reduces major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease, leading to expanded indications.
Semaglutide's success has transformed the treatment landscape for diabetes and obesity, and has spurred significant investment in peptide drug development. The demand for semaglutide and related peptides has created opportunities for peptide suppliers and CDMOs, driving expansion in peptide manufacturing capacity.
For researchers, semaglutide serves as a valuable tool for studying GLP-1 receptor signaling, investigating metabolic pathways, and developing next-generation agonists. At PeptideHub, we provide high-quality semaglutide and related peptides for research applications, with comprehensive analytical documentation to support your studies.